Quantifying the Lifetime Health and Societal Benefits from Earlier Diagnosis and Access to Approved Targeted Immunotherapies in Anti-aquaporin-4 Antibody-positive (AQP4-Ab+) Neuromyelitis Optica Spectrum Disorder (NMOSD) in the United States (P7-1.003)

Key Points

• To quantify the health and societal benefits of earlier diagnosis and access to targeted immunotherapies for AQP4-Ab+ NMOSD.
• Utilized a cohort modeling approach to assess benefits.
• Focused on patients with AQP4-Ab+ NMOSD in the United States.
• Demonstrated substantial health benefits associated with earlier diagnosis.
• Identified significant societal benefits from improved access to targeted immunotherapy.